First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (MM). To date, no randomized trial has compared VMP to Rd, and there is no evidence of the optimal treatment f...

Descripción completa

Detalles Bibliográficos
Autores principales: Larocca, Alessandra, Mina, Roberto, Offidani, Massimo, Liberati, Anna Marina, Ledda, Antonio, Patriarca, Francesca, Evangelista, Andrea, Spada, Stefano, Benevolo, Giulia, Oddolo, Daniela, Innao, Vanessa, Cangiolosi, Clotilde, Bernardini, Annalisa, Musto, Pellegrino, Amico, Valeria, Fraticelli, Vincenzo, Paris, Laura, Giuliani, Nicola, Falcone, Antonietta Pia, Zambello, Renato, De Paoli, Lorenzo, Romano, Alessandra, Palumbo, Antonio, Montefusco, Vittorio, Hájek, Roman, Boccadoro, Mario, Bringhen, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109734/
https://www.ncbi.nlm.nih.gov/pubmed/31248973
http://dx.doi.org/10.3324/haematol.2019.220657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109734/
https://www.ncbi.nlm.nih.gov/pubmed/31248973
http://dx.doi.org/10.3324/haematol.2019.220657

Ejemplares similares